| Editor's Note: Fierce's PM Tracker will be taking a break Thursday and Friday for the Thanksgiving Holiday. We'll be back in your inbox on Monday. |
|
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Today’s Big NewsNov 27, 2024 |
|
Wednesday, December 4, 2024 | 11am ET / 8am PT Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now. 
|
|
| By Fraiser Kansteiner Novartis is laying off a total of 139 staffers in East Hanover, New Jersey, where the company’s U.S. headquarters is located. The move will primarily affect commercial field sales associates working on the brands Xolair for asthma and allergies and the oncology combo made up of kinase inhibitors Tafinlar and Mekinist. |
|
|
|
By Gabrielle Masson President-elect Donald Trump has chosen Stanford University’s Jay Bhattacharya, M.D., Ph.D., to serve as the director of the National Institutes of Health. |
By Conor Hale Philips is expanding its collaboration with Amazon Web Services, to provide cloud-based imaging diagnostics spanning radiology, pathology, cardiology and AI. |
By Darren Incorvaia Proliferative vitreoretinopathy is an eye condition that leads to blindness and can currently only be addressed with surgery. A team led by research hospital Massachusetts Eye and Ear and German biotech CureVac has designed an mRNA therapy that delivered a therapeutic gene transcript to the eyes of rabbits with the disease, reducing the harmful excess of scar tissue that is characteristic of the condition. |
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now! 
|
|
By Kevin Dunleavy Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be reconfigured within days during a pandemic—the drugmaker has opened a similar facility in Singapore. |
By Fraiser Kansteiner Kronos will lay off some 83% of its workforce by the end of the year as it continues to explore options to stay afloat, including “possible business combinations” or the divesture of remaining preclinical assets. Additionally, the company's CEO, Norbert Bischofberger, Ph.D., is stepping down from his post on Dec. 3. |
By Conor Hale The company said it would allow severely paralyzed patients currently signed up to receive the implant through its PRIME safety trial to also cross-enroll in a new study, named CONVOY. |
By Kevin Dunleavy A survey of life sciences CEOs found that 94% plan to grow their workforce over the next three years, with 37% envisioning that the head count of their company will grow by at least 6%. The results back up the confidence the CEOs have in their companies’ growth prospects. |
By Gabrielle Masson Acadia Pharmaceuticals has penned an exclusive licensing deal worth up to $582 million biobucks for Saniona’s neurological disorder asset. |
By Angus Liu The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab tirumotecan has become the second therapy in the class to win a marketing approval. |
By James Waldron Idorsia may have negotiated a $35 million payday ahead of a potential licensing deal for its hypertension drug Tryvio, but that won’t be enough to save the 270 roles the company is looking to cut. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
Monday, December 16, 2024 | 1pm ET / 10am PT Join us for an insightful webinar on the evolving privacy landscape impacting pharma marketers. As state laws continue to shape advertising practices, understanding the nuances of compliance and data ethics is crucial. Register now to gain access to expert insights on sustainable privacy strategies and balancing innovation with ethical data use. 
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
